His symptoms improved on treatment with pramipexole and selegiline ... the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...

Treatment with the α-blocker doxazosin ... increased focal 131I activity that was consistent with right adrenal pheochromocytoma. The patient was advised to undergo surgical removal of the ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Fortunately, there is now an effective treatment available for patients with unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (PPGL). A recent review in Cancers from ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

for the treatment of adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The sNDA is based on objective response ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...